Insider · CIK 0002100735
Mark E. Bunnage
Files at VRTX (VERTEX PHARMACEUTICALS INC / MA). First filing Feb 12, 2026, latest May 19, 2026.
In brief
Mark E. Bunnage files SEC Form 4 as officer at VRTX (VERTEX PHARMACEUTICALS INC / MA). Since Feb 12, 2026, Mark E. Bunnage has reported 0 open-market buys worth $0 and 4 open-market sells worth $3.0M, the latest filed on May 19, 2026.
A track record needs three past buys with six months of prices behind them; Mark E. Bunnage has 0, so none is measured yet.
The newest scored trade: sold $15k of VRTX on May 15, 2026, filed May 19, 2026, scored 10 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $3.0M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
VRTX: VERTEX PHARMACEUTICALS INC / MA
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | VERTEX PHARMACEUTICALS INC / MA | $15k 33 shares | -0% | +19% from low-12% from high | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | $302k 620 shares | -8% | +32% from low-6% from high | |
| 45Moderate | VERTEX PHARMACEUTICALS INC / MA | $1.8M 3,619 shares | -30% | +30% from low-7% from high | |
| 39Weak | VERTEX PHARMACEUTICALS INC / MA | $931k 2,021 shares | -14% | +26% from low-10% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 15, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | 33 0.00% of outstanding | $15k | May 15, 2026 | $2.1M |
| Feb 25, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | 620 0.00% of outstanding | $302k | Feb 25, 2026 | $2.7M |
| Feb 18, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | 1,182 0.00% of outstanding | $560k | Feb 18, 2026 | $2.1M |
| Feb 17, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | 2,437 0.00% of outstanding | $1.2M | Feb 17, 2026 | $941k |
| Feb 11, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | 2,021 0.00% of outstanding | $931k | Feb 11, 2026 | $11k |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 15, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | SOpen-market sale Common Stock10b5-1 | -33 | $453.45 | $15k | 7,284 | May 19, 2026 |
| Feb 24, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | FTax withholding Common Stock10b5-1 | -582 | $485.11 | $282k | 7,904 | Feb 26, 2026 |
| Feb 25, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | SOpen-market sale Common Stock10b5-1 | -620 | $486.35 | $302k | 7,284 | Feb 26, 2026 |
| Feb 17, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | AGrant or award Common Stock10b5-1 | +2,584 | $0.00 | $0 | 13,215 | Feb 19, 2026 |
| Feb 17, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | FTax withholding Common Stock10b5-1 | -1,110 | $483.75 | $537k | 12,105 | Feb 19, 2026 |
| Feb 17, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | SOpen-market sale Common Stock10b5-1 | -2,437 | $489.46 | $1.2M | 9,668 | Feb 19, 2026 |
| Feb 18, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | SOpen-market sale Common Stock10b5-1 | -1,182 | $473.68 | $560k | 8,486 | Feb 19, 2026 |
| Feb 13, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | FTax withholding Common Stock | -2,283 | $487.76 | $1.1M | 10,631 | Feb 18, 2026 |
| Feb 10, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | FTax withholding Common Stock10b5-1 | -1,127 | $468.41 | $528k | 14,935 | Feb 12, 2026 |
| Feb 11, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | SOpen-market sale Common Stock10b5-1 | -2,021 | $460.43 | $931k | 12,914 | Feb 12, 2026 |
Questions about Mark E. Bunnage
Answered from the filings on this page, as of the latest one.
Is Mark E. Bunnage buying or selling?
In the last 12 months Mark E. Bunnage reported 0 open-market buys worth $0 and 4 open-market sells worth $3.0M on SEC Form 4; the latest was sold $15k of VRTX on May 15, 2026. Grants, option exercises and tax withholding are not counted.
How did Mark E. Bunnage's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark E. Bunnage has 0.
Where does Mark E. Bunnage file Form 4?
Mark E. Bunnage has filed Form 4 at VRTX (VERTEX PHARMACEUTICALS INC / MA) as EVP, Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.